Oncolytic vaccinia virus-mediated tumor cell lysis and granulocyte-macrophage colony-stimulating factor-mediated immune activation

This entry does not refer to a single molecular target such as a receptor, enzyme, or protein complex but rather describes a therapeutic strategy that combines two components: 1. Oncolytic vaccinia viruses are genetically engineered viruses that selectively infect and replicate within cancer cells—causing direct lysis—and can be further modified to express therapeutic genes such as cytokines[1][4]. Their selectivity is based on vulnerabilities unique to malignant cells—such as defects in antiviral signaling pathways—which allow the virus to replicate preferentially in tumors while sparing normal tissue[1]. 2. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an immunostimulatory cytokine often encoded within these viruses' genomes so that infected tumors locally secrete high levels after infection.[2] This enhances recruitment and maturation of antigen-presenting myeloid cells like dendritic cells and macrophages at the site where dying cancer cells release their antigens.[5] The result is improved priming and expansion of anti-tumor T-cell responses.[6] The overall effect is both direct killing of malignant tissue via viral replication/lysis and potent stimulation/recruitment/activation of host immune responses against residual disease through local delivery/expression of GM-CSF.[4] Because this entry refers to an entire process rather than one discrete molecular entity—and because it conflates two distinct mechanisms—it should not be considered a canonical drug target per se. If you require structured information about either "oncolytic vaccinia virus" or "granulocyte-macrophage colony-stimulating factor receptor," those can be provided separately as canonical targets.

Other names

Oncolytic vaccinia virus with GM-CSFOncolytic vaccinia virus expressing GM-CSFVACV-GM-CSF (informal, for engineered viruses)Tumor cell lysis by oncolytic virus and GM-CSF activation (descriptive)

1. Direct tumor cell lysis by oncolytic vaccinia virus replication within cancer cells[1][4][7]. 2. Release of danger signals and tumor antigens upon viral-induced immunogenic cell death[4][7]. 3. Activation of innate immunity via recruitment/activation of dendritic cells, macrophages, neutrophils through local expression of GM-CSF[2][5][6]. 4. Promotion of adaptive immunity, including T-cell priming against released tumor antigens facilitated by dendritic cells activated by GM-CSF[2][5].